Ann Aerts – Head, Novartis Foundation, Switzerland
Dr Ann Aerts, head of the Novartis Foundation, discusses the role the Novartis Foundation plays within low and middle- income countries across the world and how integrating digital health solutions…
Since its founding in 1943, the Swiss Tropical Institute (STI), now Swiss Tropical and Public Health Institute (Swiss TPH) has become a world-renowned Institution for teaching, research and services in the field of International Health Development.
The multi- and cross-disciplinary activities and experience of scientific laboratory studies, conceptual clinical work and practical transfer of technical expertise to health system planning and programmes in local, national and partner countries are the building blocks of the Swiss TPH´s success.
Today over 700 colleagues from 40 nations work worldwide for the Swiss TPH in research, teaching and service provision with the single goal to facilitate and contribute to health development worldwide with a strong focus on low and middle income countries.
As an associate institute of the University of Basel, the Swiss TPH takes part in teaching within the medical, philosophy, natural sciences, and historical philosophy faculties, as well as is engaged in post-graduate education and advanced training on national and international levels.
Contact
Swiss Tropical and Public Health Institute
P.O. Box
4002 Basel
Main Secretariat & Travel Clinic:
Socinstrasse 57
4051 Basel
Phone +41 61 284 81 11
Dr Ann Aerts, head of the Novartis Foundation, discusses the role the Novartis Foundation plays within low and middle- income countries across the world and how integrating digital health solutions…
Lukas Engelberger discusses the challenges and benefits of the healthcare system in Switzerland and the Canton of Basel-Stadt, new milestones in dentistry and the organizational structure between the hospitals and…
Carolin Hillebrand, country manager of Neurim Pharmaceuticals Switzerland, a neuroscience specialty company, discusses the launch of their lead product Circadin, the only IP-protected product providing a prolonged release formulation of…
CEO of Biomed, Dr. Thomas F. Szuran discusses the keys to success for pharma SMEs and the importance of relationship management, investments, and a culture of internal dialogue. Could you…
Walter Steinlin describes the Federal Commission of Technology and Innovation as a catalyst for turning research into innovation. Based in Bern, Switzerland, the commission funds research institutes in corporate projects,…
Jean-Daniel Gerber, chairman of the board at SIFEM, explains why job creation should be the focus of DFIs (Development Finance Institutions) such as SIFEM; how ESG, environmental, social and governance…
Ronald Scott, CEO of Basilea, a biotech company that was spun out of Roche in 2000, talks about launching its first two products, Zevtera and Cresemba; the milestone agreement with…
Actelion’s global CEO and co-founder, Dr Jean-Paul Clozel, discusses diversifying the company’s portfolio, prioritizing internal research over inorganic acquisitions, and retaining a spirit of independence and innovation during a period…
André Lüscher of Gilead Switzerland, reveals how the case of Sovaldi demonstrates the challenges for a healthcare system to handle a truly disruptive medical innovation, the knock-on effect on Gilead´s…
Andreas Bosshard of Mepha-Teva in Switzerland describes Switzerland’s unique generics market, the quality of the Mepha-Teva brand, innovations within generics, and the company’s growth strategy within the Swiss market. It…
Franz Saladin details the unique scope and operations of the Basel Chamber of Commerce, the history of pharmaceuticals in Basel, and the importance of continuously developing the industry within the…
Biologics giant Biogen is investing USD one billion in a next-generation manufacturing facility in Luterbach, near Solothurn, Switzerland, tripling production capacity and creating 400 new jobs. The decision to situate…
See our Cookie Privacy Policy Here
